Latest news
Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)
Debiopharm Group™ and Yale University extend and broaden their collaboration for the discovery and development of MIF inhibitors to treat…
Debiopharm Group™ to Acquire Affinium’s Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics
Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
Spinomix announces a milestone payment from Debiopharm Group™ and the appointment of a new CEO
BPA Solutions get Investment funds to accelerate rapid growth and global expansion
Atheris and Debiopharm Group™ to collaborate for the lead optimization of Debio 0826 using a “Reverse-Discovery” strategy
Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio…